Drugs that contain Carbamazepine
1. List of Carnexiv drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
| US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
| US7635773 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US8410077 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9750822 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9493582 | LUNDBECK PHARMS LLC | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 7, 2023 |
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or generalized seizures
Dosage: SOLUTION;INTRAVENOUS
2. List of Equetro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6977253 | VALIDUS PHARMS | Methods for the treatment of bipolar disorder using carbamazepine |
May, 2024
(1 year, 3 months from now) | |
Market Authorisation Date: 10 December, 2004
Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic